The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcinoma: The IMPACT study.
Marina Tschaika
Employment or Leadership Position - MOLOGEN
Hans-Joachim Schmoll
No relevant relationships to disclose
Jorge Riera-Knorrenschild
No relevant relationships to disclose
Hendrik Kröning
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Ekaterina Weith
Employment or Leadership Position - MOLOGEN
Matthias Schroff
Employment or Leadership Position - MOLOGEN
Maxim Krikov
Employment or Leadership Position - MOLOGEN
Manuel Schmidt
Employment or Leadership Position - MOLOGEN
Burghardt Wittig
Consultant or Advisory Role - MOLOGEN